This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Atreca Toekomstige groei
Future criteriumcontroles 0/6
Atreca is forecast to grow earnings at 4.3% per annum.
Belangrijke informatie
4.3%
Groei van de winst
n/a
Groei van de winst per aandeel
| Biotechs winstgroei | 35.6% |
| Inkomstengroei | n/a |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 31 May 2024 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -52 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -48 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -38 | N/A | N/A | 1 |
| 12/31/2023 | N/A | -65 | N/A | N/A | 1 |
| 9/30/2023 | N/A | -98 | -65 | -65 | N/A |
| 6/30/2023 | N/A | -85 | -65 | -64 | N/A |
| 3/31/2023 | N/A | -93 | -71 | -70 | N/A |
| 12/31/2022 | N/A | -97 | -82 | -81 | N/A |
| 9/30/2022 | N/A | -105 | -86 | -81 | N/A |
| 6/30/2022 | N/A | -110 | -88 | -81 | N/A |
| 3/31/2022 | N/A | -108 | -93 | -69 | N/A |
| 12/31/2021 | N/A | -109 | -96 | -61 | N/A |
| 9/30/2021 | N/A | -103 | -96 | -63 | N/A |
| 6/30/2021 | N/A | -98 | -93 | -62 | N/A |
| 3/31/2021 | N/A | -92 | -82 | -66 | N/A |
| 12/31/2020 | N/A | -86 | -72 | -67 | N/A |
| 9/30/2020 | N/A | -83 | -70 | -65 | N/A |
| 6/30/2020 | N/A | -76 | -71 | -65 | N/A |
| 3/31/2020 | N/A | -74 | -67 | -63 | N/A |
| 12/31/2019 | N/A | -67 | -62 | -59 | N/A |
| 9/30/2019 | N/A | -59 | -56 | -53 | N/A |
| 6/30/2019 | N/A | -53 | -47 | -45 | N/A |
| 3/31/2019 | N/A | -44 | -41 | -40 | N/A |
| 12/31/2018 | N/A | -38 | -36 | -35 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 0C1 is forecast to remain unprofitable over the next 3 years.
Winst versus markt: 0C1 is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: 0C1 is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: Insufficient data to determine if 0C1's revenue is forecast to grow faster than the German market.
Hoge groei-inkomsten: 0C1 is forecast to have no revenue next year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if 0C1's Return on Equity is forecast to be high in 3 years time